Literature DB >> 8137431

Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells.

J W Heusel1, R L Wesselschmidt, S Shresta, J H Russell, T J Ley.   

Abstract

We have generated H-2b mice with a homozygous null mutation in the granzyme (gzm) B gene. Gzm B is a neutral serine protease with Aspase activity that is found only in the granules of activated cytolytic T cells, natural killer cells, and lymphokine-activated killer cells. Gzm B-/- mice develop normally and have normal hematopoiesis and lymphopoiesis. In vitro, cytotoxic T lymphocytes (CTL) derived from gzm B-/- animals are able to induce 51Cr release from allotarget cells, but with reduced efficiency. However, gzm B-/- CTL have a profound defect in their ability to induce rapid DNA fragmentation and apoptosis in allogeneic target cells. This defect is kinetic since DNA fragmentation is partially compensated and 51Cr release is completely rescued with long incubation times. We conclude that gzm B serves a critical and nonredundant role for the rapid induction of target cell DNA fragmentation and apoptosis by alloreactive cytotoxic T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8137431     DOI: 10.1016/0092-8674(94)90376-x

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  186 in total

1.  Cleavage by granzyme B is strongly predictive of autoantigen status: implications for initiation of autoimmunity.

Authors:  L Casciola-Rosen; F Andrade; D Ulanet; W B Wong; A Rosen
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

2.  Cytosolic delivery of granzyme B by bacterial toxins: evidence that endosomal disruption, in addition to transmembrane pore formation, is an important function of perforin.

Authors:  K A Browne; E Blink; V R Sutton; C J Froelich; D A Jans; J A Trapani
Journal:  Mol Cell Biol       Date:  1999-12       Impact factor: 4.272

Review 3.  Granzyme A activates another way to die.

Authors:  Judy Lieberman
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

4.  A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer.

Authors:  Yefei Rong; Xia Qin; Dayong Jin; Wenhui Lou; Lili Wu; Dansong Wang; Wenchuan Wu; Xiaolin Ni; Zhengfa Mao; Tiantao Kuang; Ying Qin Zang; Xinyu Qin
Journal:  Clin Exp Med       Date:  2011-09-20       Impact factor: 3.984

Review 5.  Apoptosis and the balance of homeostatic and pathologic responses to protozoan infection.

Authors:  L Cristina Gavrilescu; Eric Y Denkers
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

Review 6.  Effector lymphocytes in islet cell autoimmunity.

Authors:  Pere Santamaria
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 7.  A quarter century of granzymes.

Authors:  C L Ewen; K P Kane; R C Bleackley
Journal:  Cell Death Differ       Date:  2011-11-04       Impact factor: 15.828

8.  A pro-survival role for the intracellular granzyme B inhibitor Serpinb9 in natural killer cells during poxvirus infection.

Authors:  Matthew S Mangan; Carolina R Melo-Silva; Jennii Luu; Catherina H Bird; Aulikki Koskinen; Alexandra Rizzitelli; Monica Prakash; Katrina L Scarff; Arno Müllbacher; Matthias Regner; Phillip I Bird
Journal:  Immunol Cell Biol       Date:  2017-08-15       Impact factor: 5.126

Review 9.  Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Nathan Avaritt; Henry K Wong; Laura F Hutchins; Sara Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2017-05-17       Impact factor: 4.742

10.  Transgenic mice carrying the diphtheria toxin A chain gene under the control of the granzyme A promoter: expected depletion of cytotoxic cells and unexpected depletion of CD8 T cells.

Authors:  H L Aguila; R J Hershberger; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.